Bryan B. Bushman, PhD

Bryan Bushman, Ph.D., is a licensed clinical psychologist at the McKay-Dee Behavioral Health Institute. He provides treatment for depression, anxiety, self-injurious behaviors and chronic pain. He also provides psychological and neuropsychological testing for learning problems, ADHD, cognitive delay and dysfunction, traumatic-brain injury, and mood problems. He has received specialty training in helping others cope with medical illness and neuropsychological assessment of medical diseases such as sickle cell anemia and cancer. Dr. Bushman received his undergraduate degree in psychology from the University of Texas at Austin. He completed his doctorate in clinical psychology at Utah State University. He has worked in medical and pediatric settings. Online profile
Original published date
Original source title
oneSCDvoice
Original updated date

Pacific Sickle Cell Regional Collaborative

The Pacific Sickle Cell Regional Collaborative is a federally-funded project that seeks to improve the health and quality of life of children and adults with sickle cell disease in collaboration with sickle cell disease experts, people with sickle cell disease and their family members, primary care providers, sickle cell community based organizations, policy makers, public health departments. Goals of the organisation include: • To improve accessibility to quality, coordinated, and comprehensive health care services available for individuals with SCD and their families. • To reduce morbidity and mortality caused by SCD by strengthening the network of knowledgeable providers utilizing evidence based practices in their care of adults and children with SCD. • And continue to expand data collection and processing to document regional improvements in access, capacity, and outcomes. Official website
Original published date
Original source title
oneSCDvoice
Original updated date

Hassan M. Yaish, MD

Dr. Hassan is a board certified doctor both in general paediatrics and paediatric hematology and oncology. He is currently affiliated with Primary Children's Cancer, Blood, and Marrow Clinic at Primary children’s hospital. His clinical interest is mainly in pediatric hematology with thrombocytopenia in children, neonatal hematology and bleeding disorders. Other interest lies with anemia, neutropenia and coagulation defects. He also has experience in hemoglobinopathy and thalassemia.     Representative Publications: Two novel mutations in TMPRSS6 associated with iron-refractory iron deficiency anemia in a mother and child Three Novel Spectrin Variants in Jaundiced Neonates Neonatal nonimmune hemolytic anemia Ringed sideroblasts in β-thalassemia Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anaemias Online profile
Original published date
Original source title
oneSCDvoice
Original updated date

Dana Carroll, PhD

Dana Carroll, PhD, is a distinguished professor in the Department of Biochemistry at the University of Utah School of Medicine and a member of the Nuclear Control of Cell Growth and Differentiation Program at the Huntsman Cancer Institute. Carroll’s research involves making specific changes in chromosomal DNA using targetable nucleases. His lab pioneered the development of zinc-finger nucleases as gene targeting tools, and they have continued working with the more recent TALENs and CRISPR/Cas nucleases. Much of the effort has been focused on optimizing the efficiency of these reagents for targeted mutagenesis and gene replacement, which could ultimately provide treatment for many diseases, including sickle cell disease. This technology has now been applied to more than 40 different organisms, including current clinical trials in humans.   Representative Publications: Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells Online profile
Original published date
Original source title
oneSCDvoice
Original updated date

Seethal Jacob, MD

Dr. Seethal Jacob is a pediatric hematologist-oncologist in Indianapolis, Indiana and is affiliated with multiple hospitals in the area, including Indiana University Health North Hospital and Indiana University Health University Hospital. She received her medical degree from Wright State University Boonshoft School of Medicine and has been in practice between 6-10 years. She is one of 15 doctors at Indiana University Health North Hospital and one of 20 at Indiana University Health University Hospital who specialize in Pediatric Hematology-Oncology. Online profile
Original published date
Original source title
oneSCDvoice
Original updated date

Tonymay Foundation

Tonymay foundation is a non-profit organisation incorporated with the Nigerian Corporate Affairs Commission in 2011. The aim of this organization is to have a sickle cell free nation and advocate for a sickle cell policy in the treatment and management of sickle disorder in Nigeria. Its action plan is to engage communities and the populace on the need for a collective effort on the fight against sickle cell disorder that has become endemic in the nation and get government support for people living with SCD. Tonymay foundation conducts a monthly SCD clinic for people living with the disorder where free medical consultation and free drugs are given to patients that cover Oriade, Amuwo-Odofin, OlodiApapa, Ajeromi and Ojo areas of Lagos state. Tonymay foundation also offers assistance to patient with severe SCD cases and complications that arises from the disorder. They rely on donations from donors and sponsors (individual and corporate) to achieve our goal of a sickle cell free nation. Official website
Original published date
Original source title
oneSCDvoice
Original updated date

DanceBlue inspired UK alumnus to study and fight health disparities

Jordan McDowell, a 2014 alumnus of the University of Kentucky, has always been interested in the ways having a child with a chronic illness affects families. Part of this interest comes from his own experience with sickle cell disease.McDowell knows first-hand the experiences and difficulties a child with a chronic illness can have when transitioning from their parents' care to a new environment like college. As a child, McDowell was diagnosed with sickle cell disease, a severe hereditary form of anemia in which a mutated form of hemoglobin distorts the red blood cells into a crescent shape which can block blood flow and cause severe pain. Related story
Original published date
Original source title
oneSCDvoice
Original updated date

Developmental outcomes of children exposed to maternal sickle cell disease (SCD)

BACKGROUND: Pregnant women with SCD have an increased risk of both maternal and fetal complications, including preeclampsia, venous thromboembolism, and cardiomyopathy, as well as an increased risk of intrauterine growth restriction, preterm birth, low birth weight, and fetal demise. While in general children with a history of intrauterine growth restriction are at risk for abnormal neurodevelopment as well as later obesity and metabolic syndrome, the long-term developmental outcomes of children without SCD but exposed to maternal SCD are unknown. Better data about the long-term developmental outcome for children of mothers with SCD will provide guidance about the utility of disease modifying therapy during pregnancy. The objective of this study is to explore outcomes for children born to mothers with SCD using data from the Boston Birth Cohort (BBC). METHODS: The BBC is a prospective birth cohort established in 1998 at the Boston Medical Center (BMC) that recruits preterm cases (born at less than 37 weeks gestation) and full term controls. The BBC enrolls predominantly urban, low-income minority mothers and their children 24-72 hours after delivery at the BMC and follows the children from birth up to age 21 years. Data is collected on maternal preconception medical conditions, pregnancy complications, and pregnancy exposures through structured interviews at the time of enrollment and medical record extraction. Data on child development is collected from medical records and structured interviews performed by trained study staff at their scheduled pediatric appointments. Approximately 38% of study participants self-identify as black/African American, 22% as Hispanic, 19% as Haitian, and 8.5% as white. From maternal electronic medical record data capturing 147,827 emergency room and outpatient visits contributed by 5,972 subjects, we identified all women with ICD-9-CM codes for sickle cell disease (282.60-64, 282.68, 282.69, 282.41, 282.42) and probable (two or more 282.62 codes) sickle cell anemia. We then linked maternal and child data on the basis of a unique family-level study ID. Information on child development was obtained from electronic medical record data, based on the presence of relevant ICD-9-CM hospital diagnosis codes from pediatric outpatient, inpatient, and emergency room visits. RESULTS: We identified 93 women who had at least one of the ICD-9 codes for SCD. For this report we have included only those forty-one women who were coded at least twice with a 282.62 diagnosis (Hemoglobin SS disease with crisis). Six (15%) had poor fetal growth during their pregnancy, while eight (20%) were diagnosed with preeclampsia or antepartum hypertension. Among these mothers with available questionnaire and medical record extraction data (n = 38), 7 (18%) delivered their children before 37 weeks gestation, and 6 (16%) had children weighing less than 2500 grams at birth. Twenty mothers had children who received pediatric care at the Boston Medical Center, with ages ranging from 2 to 9 years of age; one was diagnosed with SCA, while 19 are unaffected carriers. Among the 19 children without SCD with available follow-up data, 5 (26%) carried a diagnosis code of overweight/obesity; their mothers were seen for an average of 73 medical visits (SD 50) during their pregnancy. Five children, without any overlap with the children diagnosed with obesity, were diagnosed with failure to thrive; while not statistically significantly different, their mothers had fewer medical encounters (mean 55, SD 37). Five children were diagnosed with delayed milestones, two of whom were late preterm (35 and 33 weeks gestation); two of these children were diagnosed with obesity and two with failure to thrive. Abstract source
Original published date
Original source title
oneSCDvoice
Original updated date

A single center experience of GBT440 treatment of severe anemia in sickle cell disease

Background: GBT440 is an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, thereby inhibiting HbS polymerization. Clinical trials assessing efficacy and safety in SCD are underway including a randomized Phase 3 study. Patients with SCD and severe anemia, i.e. Hb < 6.5 g/dL, are excluded from the trials of GBT440 but represent a major unmet need. To further describe the emerging clinical profile of GBT440, we summarize the experience of seven patients with severe anemia refractory to conventional therapy who were treated with GBT440 for up to 15 months under the GBT Expanded Access Program. Methods: Once-daily GBT440 began at 900 mg. Initial assessments at 2 and 4 weeks were followed by routine evaluations at least monthly. Table 2 shows the key tests. Baseline echocardiograms were performed. PHQ-9 assessment at each visit gauged depression and was accompanied by a simple 1-10 pain score index. All transfusions and hospitalizations were captured. Results: Tables 1 and 2 summarize the patient clinical characteristics and laboratory data. In 5/7 patients, baseline Hb was < 6.4 g/dL with two < 6 g/dL, including pt A who was alloimunized and refractory to transfusion. The other 6 patients received intermittent transfusions, often associated with VOC admissions. Except for pt D who was non-adherent, GBT440 increased Hb in all patients and the increase exceeded 2 g/dL in two. In 4 of the 6 tranfusable patients, transfusions fell by at least half comparing similar time periods before and after GBT440. VOC admissions fell by 60%. Daily background pain also decreased as assessed by 1-10 pain scale. In three patients with resting RA O2 sat =< 90% (A, C, E) values rose to 98-99% and two (A,E) ceased chronic supplemental O2. Pts A and B have received GBT440 for more than 15 months. All patients experienced striking improvement in overall well-being and reduced fatigue, most often within 2 to 3 weeks of starting GBT440. In most, mood improved and depression lessened as assessed by PHQ-9. GBT440 was well-tolerated with no dose reductions or discontinuations at 900 mg. An increase to 1500 mg in Pt A caused grade 2 diarrhea which resolved with a return to 900 mg. No GBT440-related SAE occurred. Pt C died in the setting of ACS, unrelated to GBT440. Conclusion: In these 7 SCD patients with severe anemia who were not eligible for the Phase 3 clinical program, GBT440 administered via the EAP substantially improved a variety of clinical, laboratory and PRO parameters. Controlled clinical trials will be needed to confirm the benefit of GBT440 in patients with severe anemia. Abstract source
Original published date
Original source title
oneSCDvoice
Original updated date